辉瑞被“B7-H4”绊了一跤

Ofweek维科网
07 Feb

当辉瑞在2月4日的财报电话会上宣布计提29亿美元无形资产减值时,市场的目光再次聚焦ADC赛道。其中,10亿美元的“沉没成本”,直指其B7-H4 ADC药物Felmetatug vedotin的研发终止。B7-H4,这个曾被寄予厚望的ADC新兴靶点,再次迎来一大挫折。尽管Felmetatug vedotin早期临床数据不错,但辉瑞认为最新数据不足以改变现有标准疗法,因此,其决定终止研发。这并非B7-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10